{"id":14698,"date":"2026-05-13T10:33:54","date_gmt":"2026-05-13T08:33:54","guid":{"rendered":"https:\/\/optano.com\/?p=14698"},"modified":"2026-05-13T10:33:56","modified_gmt":"2026-05-13T08:33:56","slug":"insights-new-us-tariffs-for-the-pharmaceutical-industry","status":"publish","type":"post","link":"https:\/\/optano.com\/en\/media\/insight\/2\/insights-neue-us-zollplaene-fuer-die-pharmaindustrie\/","title":{"rendered":"Insights: New US tariff plans for the pharmaceutical industry"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

New US tariff plans for the pharmaceutical industry<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

When customs duties suddenly call supply chains into question<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

What appears to be a foreign trade issue is quickly becoming a planning problem in the pharmaceutical industry. Since the new US tariff plans, it is no longer just the level of tariffs that is relevant for many pharmaceutical companies, but the question of whether their supply chain can react quickly enough to new rules.<\/p>

Anyone producing pharmaceuticals for the US market is not dealing with a simple surcharge. Different requirements apply depending on the product, patent status, origin and company constellation. This means that a trade policy signal very quickly becomes an operational question: which products can continue to run as before, where does margin pressure arise and at what point does a previously stable structure topple?<\/p>

This is highly relevant for pharmaceutical companies in Europe. In 2025, the USA was the most important sales market outside the EU for pharmaceutical products. If the framework conditions shift there, it is not enough to just look at prices or tariffs. The entire decision-making structure behind it must then be reassessed.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201eNew US tariff plans affect pharmaceutical companies not only in terms of price, but in their entire supply chain logic.\u201c<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

In the pharmaceutical industry, tariffs never only affect costs<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The problem begins long before crossing the border<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In many industries, a new tariff rate can be read first and foremost as a cost issue. In the pharmaceutical industry, this view is too short-sighted. As soon as a patented product for an important export market becomes more expensive or more complicated in regulatory terms, several decisions are set in motion at the same time: Production allocation, active ingredient supply, packaging and release logic, safety stocks, prioritization of scarce capacities and, in case of doubt, even the question of which market to serve first.<\/p>

In addition, the US regulation is differentiated. It is not a blanket 100 percent case for everything that goes from Europe to the USA. It is precisely this differentiation that makes the situation operationally challenging. If you plan too roughly, you simplify the problem incorrectly. If you calculate manually for too long, you can't keep up with the dynamics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201eThe real risk lies less in individual tariff rates than in rigid networks that are difficult to plan around.\u201c<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The real weakness lies deeper<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The new customs plans come up against an industry whose supply chains were already under pressure. European institutions have long been dealing with the dependency on active pharmaceutical ingredients (APIs), scarce production capacities, bottlenecks in critical medicines and the question of how security of supply can be organized beyond classic efficiency logic. The fact that strategic stockpiling, transparency in the supply chain and more resilient production structures are being discussed at the same time shows that vulnerability is structural: The vulnerability is structural.<\/p>

A company can therefore operate cleanly in regulatory terms and still fall into an operational trap. Not because a plant suddenly comes to a standstill, but because the existing structure was built for stability, not for differentiated customs regimes, erratic tariff increases and volatile allocation decisions.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The critical moment is rarely spectacular<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This is illustrated by a simple scenario: a patented specialty product continues to be supplied from a European site to the USA. The active ingredient is in short supply, the release processes are tightly timed and additional stocks cannot be built up indefinitely due to limited shelf life and high capital commitment. As soon as the dependency on the US market changes, it is no longer enough to write the customs rate in an Excel column. A new decision must then be made on how to allocate material, whether production steps should be assigned differently and which supply line makes economic sense without jeopardizing regulatory stability.<\/p>

This is precisely where the real problem lies: the bottleneck is not in individual tariffs, but in the lack of ability to resiliently reorganize several interdependent decisions at the same time.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201eOptimization becomes relevant when costs, supply, approvals and capacities have to be rebalanced at the same time.\u201c<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

What makes mathematical optimization different in this situation<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

From individual problems to decision logic<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mathematical optimization not only helps because it calculates faster. Its value lies in the fact that it turns a confusing situation into a structured decision-making logic. Instead of looking at costs, stocks, capacity utilization or service one after the other, it evaluates these factors together.<\/p>

The question is then no longer just: \u201eWhat is the duty rate for this product?\u201c Rather: \u201eWhich combination of production location, material flow, inventory position, capacity utilization and market allocation leads to the best resilient result under the current conditions?\u201c In the pharmaceutical industry, this result is almost never purely cost-minimal. Supply, regulatory stability, delivery capability and economic viability must be considered at the same time.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Which levers must be considered together<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In practice, this means that products must be segmented, markets prioritized and material flows evaluated in a differentiated manner. For a portfolio that is heavily dependent on the US market, it may make sense to manage certain items differently to generic or less critical products. Active ingredients and critical starting materials must not be considered in isolation, but in connection with demand, release capacity, transportation routes and safety stocks.<\/p>

Often, the greatest leverage lies not in a far-reaching shift, but in a more precise allocation: a different transport or supply route, a changed packaging logic, a new prioritization of production slots or a different allocation of scarce APIs. Operationally, this can make the difference between controlled margin pressure and a chain of subsequent problems.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Further interesting content<\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t